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Abstract— The regioselective 2- or 5-arylation of imidazole derivatives with aryl halides using palladium catalysts has been described in 
recent years; whereas the arylation at both C2 and C5 carbons of imidazoles in high yields has not been performed.  We found conditions 
allowing the access to these 2,5-diarylimidazoles via a one pot reaction.  The choice of the base was found to be crucial to obtain these 
products in high yields.  Using CsOAc as the base, DMA as the solvent and only 2 mol% of the phosphine-free Pd(OAc)2 the catalyst, the 
target 2,5-diarylated imidazoles were obtained in moderate to good yields with a wide variety of aryl bromides.  Substituents such as 
fluoro, trifluoromethyl, formyl, acetyl, propionyl, ester, nitro or nitrile on the aryl bromide were tolerated.  Sterically congested aryl 
bromides or heteroaryl bromides can also be employed.  Surprisingly the nature of the substituent at position 1 on the imidazole derivative 
exhibits a huge influence on the reaction. © 2014 Elsevier Science. All rights reserved 
——— 
* Corresponding author. Tel.: 00-33-2-23-23-63-84; fax: 00-33-2-23-23-69-39; e-mail: henri.doucet@univ-rennes1.fr  
1. Introduction 
Aryl-substituted imidazoles including 2,5-
diarylimidazoles are important structures due to their 
biological properties.  For example, Fenflumizol and 
Trifenagrel are platelet aggregation inhibitors (Fig 1). 
N
N
HF
OMe
F
OMe
Fenflumizol
N
N
H
Trifenagrel
O
Me2N
Figure 1.  Examples of bioactive 2,5-diarylimidazoles 
Suzuki, Stille or Negishi palladium-catalysed cross-
coupling reactions are among the most efficient methods 
to prepare 2,5-diarylimidazoles.
1
  However, they require 
the previous preparation of an organometallic derivative.  
As early as 1990, Ohta et al. reported that the direct 
arylation of heteroaromatics with aryl halides via a C–H 
bond activation proceed in moderate to good yields using 
Pd(PPh3)4 as the catalyst.
2
  Since these exciting results, 
the Pd-catalysed direct arylation of heteroaryls using aryl 
halides as coupling partners has proved to be a very 
powerful method for a simpler and greener access to a 
wide variety of arylated heterocycles, as the major by-
products of the reaction are a base associated to HX, 
instead of metallic salts produced under more classical 
cross-coupling procedures.
3
  Moreover, the method avoids 
the preliminary preparation of an organometallic 
derivative.  However, so far, the direct arylation of 
imidazoles has attracted less attention than the arylation 
of thiophenes or thiazoles, and in most cases mono-
arylations have been described.
4-6
  The first example of 
direct 5-arylation of imidazoles using chloropyrazines as 
coupling partners and 5 mol% Pd(PPh3)4 as the catalyst 
was reported by Ohta and co-workers in 1992.
4
  Since 
these results, several groups described conditions 
allowing the intermolecular Pd-catalysed direct 2- or 5-
arylation of imidazoles.
5,6
   
So far, to our knowledge, only a few examples of Pd-
catalysed arylations at both C2 and C5 carbons of 
imidazoles in one pot have been described.7-9  In 1998, 
Miura et al. reported the regioselectivity of the arylation 
of 1-methylimidazole using various reaction conditions.
8a
  
In the presence of bromobenzene, they observed the 
formation of a mixture of 5-arylation and 2,5-diarylation 
products in a 54:24 ratio (Scheme 1, top).  They also 
reported that the addition of 2 equiv. of CuI to the 
reaction mixture, using iodobenzene as the coupling 
partner, drastically modify the selectivity of the reaction, 
as a mixture of C2 and C2,C5 arylation products in a 
37:40 ratio was obtained.  It should be noted that CuI 
itself promotes the C2 arylation of imidazole.  Bellina, 
Rossi and co-workers also studied the influence of several 
parameters for the arylation of imidazoles, and succeeded 
in a few cases to obtain directly the 2,5-diarylated 
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imidazoles although in moderate yields.8b  A few 2,5-
diarylimidazoles have also been prepared by Shibahara, 
Murai et al. using a 1,10-phenanthroline containing Pd 
catalyst and aryl iodides as coupling partners.
9
  However, 
so far sequential Pd-catalysed direct arylations remains 
the most reliable method to prepare 2,5-diarylimidazoles 
in good yields.
10
   
+
CuI (3 equiv.), DMF,
CsF, 140 °C, 114 h
N
N
Pd(OAc)2 10 mol%
PtBu3 20 mol%
I
N
N
Miura8a
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21%
+
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N
N
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Scheme 1.  Reported examples of Pd-catalysed one pot 
access to 2,5-diarylimidazoles 
Therefore, the discovery of effective conditions, for the 
direct coupling of aryl halides at both C2 and C5 positions 
of imidazole derivatives in one pot, would constitute a 
considerable advantage allowing a simpler access to 2,5-
diarylimidazoles.   
Here, we wish to (i) report that Pd(OAc)2 catalyst without 
any additional ligand promotes the direct access to 2,5-
diarylimidazoles in one pot, (ii) report on the reaction 
scope using a large set of electronically and sterically 
diverse aryl bromides, (iii) reveal the influence of the 
imidazole N-substituent. 
2. Results and discussion 
We have recently reported the direct 5-arylation of a 
range of imidazole derivatives using a phosphine-free 
palladium catalyst.
11
  Based on these results, for this study 
DMA was initially chosen as the solvent and KOAc as the 
base.  The reactions were performed at 150 °C under 
argon in the presence of Pd(OAc)2 catalyst.  Using only 
0.5 mol% Pd(OAc)2, the reaction of 3 equiv. of 4-
bromochlorobenzene with 1 equiv. of 1-methylimidazole
affords the mono- and di-arylation products 1a:1b in a 
73:27 ratio and the target product 1b was isolated in a low 
yield of 18% (Table 1, entry 1).  Then, we examined the 
influence of the amount of catalyst and base for this 
reaction (Scheme 2, Table 1, entries 2-5).  A larger excess 
(4 equiv.) of KOAc base affords the products 1a:1b in a 
68:32 ratio.  In the presence of 1 or 2 mol-% Pd(OAc)2
instead of 0.5 mol%, an almost equimolar mixture of 
1a:1b was obtained.  A longer reaction time (48 h instead 
on 20 h) led to products 1a:1b in 23:77 ratio and 1b was 
isolated in 62% yield (Table 1, entry 5).  An important 
effect of the acetate anion was observed.  The use of 
CsOAc instead of KOAc in the presence of 2 mol% 
Pd(OAc)2 gave 1a:1b in 12:88 ratio and 1b in 70% yield; 
whereas, NaOAc (2 equiv.) led to products 1a:1b in 89:11 
ratio and allowed to isolate 1a in 64% yield (Table 1, 
entries 8 and 10).  A lower reaction temperature (120 °C) 
affords products 1a:1b in 92:8 ratio (Table 1, entry 9). 
Scheme 2. 
Table 1. Influence of the reaction conditions for palladium catalysed arylation of 1-methylimidazole with 4-
bromochlorobenzene (Scheme 2) 
Entry Catalyst (mol%) Base (equiv.) Time (h) Ratio 1a:1b Yield in 1b (%) 
1 0.5 KOAc (3) 20 73:27 18 
2 0.5 KOAc (4) 20 68:32 
3 1 KOAc (4) 20 52:48 
4 2 KOAc (4) 20 52:48 
5 1 KOAc (4) 48 23:77 62 
6 1 KOAc (3)  Cs2CO3 (3) 20 44:56 
7 1 CsOAc (4) 48 15:85 
8 2 CsOAc (4) 48 12:88 70 
9 2 CsOAc (4) 48 92:8a
10 0.5 NaOAc (2) 20 89:11b 64 
Conditions: Pd(OAc)2 0.5-2 mol%, 4-bromochlorobenzene (3 equiv.), 1-methylimidazole (1 equiv.), DMA, 150 °C, 20 h, isolated yields. 
a 120°C. b 4-
Bromochlorobenzene (1.2 equiv.), 1-methylimidazole (1 equiv.), yield in 1a. 
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Then, using the most effective reaction conditions (DMA, 
CsOAc, Pd(OAc)2, 150 °C, 48 h) we explored the scope 
of this reaction using para-, meta- and ortho-substituted 
aryl bromides and also some heteroaryl bromides 
employing 1-methylimidazole as the coupling partner 
(Scheme 3, Table 2). 
First, we investigated the reaction of 1-methylimidazole 
with several para-substituted aryl bromides (Scheme 3, 
Table 2).  In most cases, the reaction proceeds very 
smoothly in the presence of 2 mol% Pd(OAc)2 catalyst.  
With electron deficient aryl bromides such as 4-
bromoacetophenone, 4-bromopropiophenone, ethyl 4-
bromopropionate, 4-bromobenzaldehyde or 4-
bromobenzonitrile, yields of 55-65% in 2-6 were 
obtained (Table 2, entries 1-5).  We also obtained 
satisfactory results using 4-fluorobromobenzene, 
bromobenzene or even the electron-rich 4-bromotoluene 
and 4-bromoanisole to afford 8-11 in 78-81% yields 
(Table 1, entries 7 and 10).  On the other hand, the use of 
4-bromonitrobenzene affords the diarylated imidazole 7
in only 32% yield due to the formation of a large amount 
of mono-arylated 1-methylimidazole (Table 2, entry 6).  
The general pattern revealed by these results shows that 
the electron-withdrawing substituents are slightly less 
favourable to obtaining the desired 2,5-diarylimidazoles.  
The presence of an electron-deficient aryl group at C5 of 
imidazole appears to disfavour the second arylation at 
carbon C2. 
The influence of the presence of meta-substituents on the 
aryl bromide is also reported in the Table 2.  As 
expected, relatively similar yields than in the presence of 
the para-substituted substrates were obtained for the 
reactions performed with 3-bromobenzonitrile, 3-
(trifluoromethyl)bromobenzene or 3-bromotoluene using 
again 2 mol% Pd(OAc)2 catalyst (Table 2, entries 12-14).  
3-Bromonitrobenzene, affords 12 in higher yield than the 
reaction performed with 4-bromonitrobenzene (Table 2, 
entry 11).  Surprisingly, with 3,5-
bis(trifluoromethyl)bromobenzene, a mixture of di- and 
tri-arylation products 16a and 16b was obtained in a 
57:43 ratio (Table 2, entry 15).   
Then, we examined the reactivity of 1-methylimidazole 
with a set of ortho-substituted aryl bromides.  Ortho-
substituents on the aryl bromides generally have an 
important effect on the reaction rates of palladium-
catalysed reactions due to their steric and/or coordination 
properties.  The expected 2,5-diaryl-1-methylimidazoles 
17-19 were obtained in moderate to good yields.  In 
some cases, similar yields than in the presence of the 
para-substituted aryl bromides were obtained.  For 
example, the coupling of 2-bromobenzonitrile or 2-
fluorobromobenzene proceeds nicely to afford 17 and 18
in 78% and 59% yields, respectively (Table 4, entries 16 
and 17).  Heteroaryl bromide, 3-bromopyridine was also 
found to be a suitable reactant, as 20 was obtained in 
72% yield (Table 2, entry 19). 
+
DMA, CsOAc,
150 °C, 48 h
N
N
Pd(OAc)2 2mol%
Br
N
N
2-20
R
R
R
Scheme 3. 
Table 2. Palladium catalysed diarylation of 1-methylimidazole with aryl bromides (Scheme 3) 
Entry Aryl bromide Product Yield (%) 
1 Br
O
2 
59 
2 
Br
O 3
65 
3 
Br
O
O
4 
55 
4 
Br
O
5 
62 
5 BrNC
6
60 
6 BrO2N
7
32 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
Tetrahedron 4
7 BrF
8
78 
8 Br
9
80 
9 BrMe
10
81 
10 BrMeO
11
78 
11 Br
O2N
12
62 
12 Br
NC
13
60 
13 Br
F3C
14
59 
14 Br
Me
15
79 
15 Br
F3C
F3C 16a
48a
16 
Br
CN
17
78 
17 
Br
F
18
59 
18 
Br
19
54 
19 
N
Br
20
72 
Conditions: Pd(OAc)2 (0.02 equiv.), ArBr (3 equiv.), 1-methylimidazole (1 equiv.), CsOAc (4 equiv.), DMA, 150 °C, 48 h, isolated yields. 
a The formation 
of a large amount of tri-arylation product 16b was observed (ratio 16a:16b  57:43). 
With 1-n-butylimidazole, using similar reaction conditions, 
low yields of the desired 2,5-diarylation products 21b-23b
were obtained (Scheme 4).  Surprisingly, with this 
imidazole derivative the formation of very large amounts of 
mono-arylation products was observed.  With 4-
bromochlorobenzene or 4-bromotoluene, mono-arylation 
products 21a and 23a and di-arylation products 21b and 
23b were formed in 71:29 and 69:31 ratios, respectively.  
These results reveal that, unexpectedly the presence of a n-
butyl substituent instead of a methyl substituent at position 
1 of an imidazole dramatically decreases its reactivity for 
the second arylation at C2.   
+
DMA, CsOAc, 150 °C, 48 h
N
N
Pd(OAc)2 2 mol%
nBu
N
N
nBu
ArBr
R
4-Cl
3,5-diCF3
4-Me
b
N
N
nBu
a
Ratio a :b
71:29
14:43:43*
69:31
Yield in b (%)
24
35
25
1 equiv.
3 equiv.
Product
21a:21b
22a:22b:22c
23a:23b
R
R
R
*: 2,4,5-Triarylation product 22c also obta ined in 43% selectivity and 33% yield
Scheme 4. 
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In order to gain more insight into the lower reactivity of 1-
n-butylimidazole vs 1-methylimidazole, a competition 
reaction to probe the substituent preference of this catalyst 
system for such couplings was performed (Scheme 5).  
From an equimolar mixture of 1-methylimidazole and 1-n-
butylimidazole using 6 equiv. of 4-bromochlorobenzene as 
the coupling partner, in the presence of 2 mol-% Pd(OAc)2
catalyst, the formation of a mixture of 1a:1b:21a:21b in a 
27:27:43:3 ratio was observed.  This result confirms that a 
n-butyl substituent at position 1 of imidazole is strongly 
deactivating for the second arylation.   
+
DMA, CsOAc (4 equiv.),
150 °C, 48 h
N
N
Pd(OAc)2 2 mol%Me
N
N
R
ArBr
Cl
Cl
R
Me
nBu
b
N
N
R Cl
a
Ratio 1a:1b:21a :21b
27:27:43:3
1 equiv.
N
N
nBu
1 equiv.
Products
1a, 1b
21a, 21b
6 equiv.
Scheme 5. 
The influence of an aryl group at position 1 on imidazole 
was also investigated (Scheme 6).  This copper and 
phosphine-free procedure was found to afford selectively 
in all cases the mono C5-arylated products 24a-27a.  The 
presence of a para-methoxy or a para-formyl substituent 
on the 1-arylimidazole has a minor influence on the 
selectivity and yield of the reaction.  Again, the presence 
of trifluoromethyl substituents on bromobenzene favours 
the formation of 2,5-diarylated products 25b and 27b
although in very low yields. 
+
DMA, CsOAc, 150 °C, 48 h
N
N
Pd(OAc)2 2 mol%
N
N Ar
ArBr
b
Ar
R R
R
OMe
OMe
CHO
CHO
Ar
4-ClC6H4
3,5-di(CF3)C6H3
4-ClC6H4
3,5-di(CF3)C6H3
Yield in a (%)
62
75
53
52
Ratio a:b
100:0
87:13
100:0
95:5
Product
24a:24b
25a:25b
26a:26b
27a:27b
N
N Ar
a
R
+
3 equiv.
1 equiv.
Scheme 6. 
We then turned our attention to the reactivity of 1-
benzylimidazole for the Pd-catalysed 2,5-diarylations, as 
the deprotection of imidazoles bearing benzyl substituents 
is easier than the corresponding 1-methylimidazoles 
(Scheme 7).  We selected our previous best reaction 
conditions, i.e, 2 mol% Pd(OAc)2 catalyst in the presence 
of 4 equiv. of CsOAc as base in DMA at 150 ºC.  In the 
presence of 4-bromobenzonitrile, only the formation of the 
mono-5-arylated imidazole 28a, without cleavage of the 
benzyl group, was observed.  On the other hand, the 
reaction with 3,5-bis(trifluoromethyl)bromobenzene affords 
a mixture of the mono- di- and tri-arylation products 29a, 
29b and 29c in a 15:40:45 ratio.  From 4-
chlorobromobenzene and 4-bromotoluene, mixtures of 
mono- and di-arylation products were obtained.  These 
selectivities are very similar to those observed in the course 
of the coupling with 1-n-butylimidazole (Scheme 2).  
Therefore, for the access to N-benzyl substituted 2,5-
diarylimizazoles, the sequential arylation procedure 
reported by Bellina, Rossi et al. using 5 mol% Pd(OAc)2
associated to 2 equiv. of CuI for the second arylation at C2 
should be preferred.
10a
+
DMA, CsOAc, 150 °C, 48 h
N
N
Pd(OAc)2 2 mol%
N
N Ar
ArBr
b
Ar
Ph
Ar
4-CNC6H4
3,5-di(CF3)C6H3
4-ClC6H4
4-MeC6H4
Yield in a (%)
41
32 of 29b
44
31
Ratio a:b
100:0
15:40:45
70:30
50:50
Product
28a:28b
29a:29b:29c*
30a:30b
31a:31b
N
N Ar
a
Ph
+
3 equiv.
1 equiv.
Ph
*: 2,4,5-Triarylation product 29c also obtained in 45% selectivity and in 34% yield
Scheme 7.
In conclusion, we report here for the first time a simple 
one-pot catalytic method leading to the direct synthesis of 
2,5-diarylimidazoles in good yields.  We have established 
that, a phosphine-free and copper-free procedure using 
Pd(OAc)2 catalyst, CsOAc as base in the presence of aryl 
bromides as coupling partners promotes the 2,5-diarylation 
of 1-methylimidazole.  A wide range of functions such as 
fluoro, acetyl, formyl, propionyl, carboxylate, nitrile or 
nitro on the aryl bromide are tolerated.  Some sterically 
hindered aryl bromides and heteroaromatic substrate 3-
bromopyridines have also been employed successfully.  
The substituents at position 1 on imidazole were found to 
exhibit a very important influence on the products 
distribution.  It should be noted that, despite their interest, 
most of the products prepared by this method are new, 
indicating a relatively limited access to such compounds 
using more traditional cross-coupling procedures.  This 
procedure employs a commercially available, phosphine-
free and air stable palladium source.  Therefore, there is no 
need to eliminate phosphine derivatives at the end of the 
reaction.  Moreover, a very wide variety of aryl bromides 
are commercially available.  These are practical advantages 
of this reaction. 
3. Experimental
General Remarks: All reactions were run under argon in 
Schlenk tubes using vacuum lines.  DMA analytical grade 
was not distilled before use.  CsOAc (99%) was used.  
Commercial aryl bromides and imidazoles were used 
without purification.  The reactions were followed by GC 
and NMR.  
1
H and 
13
C spectra were recorded with a Bruker 
400 MHz spectrometer in CDCl3 solutions.  Chemical 
shifts are reported in ppm relative to CDCl3 (7.25 for 
1
H 
NMR and 77.0 for 
13
C NMR).  Flash chromatography was 
performed on silica gel (230–400 mesh). 
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Experimental section 
General procedure 
In a typical experiment, the aryl bromide (3 mmol), 
imidazole derivative (1 mmol), CsOAc (1.303 g, 4 mmol) 
and Pd(OAc)2 (4.4 mg, 0.02 mmol), were dissolved in 
DMA (5 mL) under an argon atmosphere.  The reaction 
mixture was stirred at 150 °C for 48h.  After evaporation of 
the solvent, the product was purified by silica gel column 
chromatography. 
5-(4-Chlorophenyl)-1-methylimidazole (1a)
8c
From 4-bromochlorobenzene (0.230 g, 1.2 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and NaOAc (0.164 g, 2 
mmol) with Pd(OAc)2 (1.1 mg, 0.005 mmol), product 1a 
was obtained in 64% (0.123 g) yield.  1H NMR (400 MHz, 
CDCl3) δ  7.44 (s, 1H), 7.32 (d, J = 8.4 Hz, 2H), 7.22 (d, J 
= 8.4 Hz, 2H), 7.01 (s, 1H), 3.57 (s, 3H). 
2,5-Bis(4-chlorophenyl)-1-methylimidazole (1b) 
From 4-bromochlorobenzene (0.574 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 1b 
was obtained in 70% (0.212 g) yield.  
1
H NMR (400 MHz, 
CDCl3) δ  7.56 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 8.4 Hz, 
2H), 7.37 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 7.12 
(s, 1H), 3.58 (s, 3H).  
13
C NMR (100 MHz, CDCl3) δ
148.2, 135.3, 134.6, 134.4, 130.1, 129.9, 129.2, 129.0, 
128.5, 128.2, 127.1, 33.9.  C16H12Cl2N2 (303.19): Calcd C 
63.38, H 3.99, N 9.24; Found C 63.55, H 4.09, N 9.14. 
1,1'-(4,4'-(1-methylimidazole-2,5-diyl)bis(4,1-
phenylene))diethanone (2)
7b
  
From 4-bromoacetophenone (0.597 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 2 was 
obtained in 59% (0.187 g) yield.  
1
H NMR (400 MHz, 
CDCl3) δ  8.02 (d, J = 8.4 Hz, 2H), 7.99 (d, J = 8.4 Hz, 
2H), 7.77 (d, J = 8.4 Hz, 2H), 7.51 (d, J = 8.4 Hz, 2H), 7.28 
(s, 1H), 3.70 (s, 3H), 2.60 (s, 3H), 2.59 (s, 3H).  
1,1'-(4,4'-(1-Methylimidazole-2,5-diyl)bis(4,1-
phenylene))dipropan-1-one (3) 
From 4-bromopropiophenone (0.639 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 3 was 
obtained in 65% (0.225 g) yield.  
1
H NMR (400 MHz, 
CDCl3) δ  8.02 (d, J = 8.4 Hz, 2H), 7.98 (d, J = 8.4 Hz, 
2H), 7.75 (d, J = 8.4 Hz, 2H), 7.50 (d, J = 8.4 Hz, 2H), 7.27 
(s, 1H), 3.71 (s, 3H), 2.95 (q, J = 7.5 Hz, 4H), 1.15 (t, J = 
7.5 Hz, 6H).  13C NMR (100 MHz, CDCl3) δ 200.1, 200.0, 
149.0, 136.9, 136.2, 135.3, 134.1, 133.9, 128.9, 128.6, 
128.4, 128.3, 34.4, 32.0, 31.9, 8.3, 8.2.  C22H22N2O2
(346.42): Calcd C 76.28, H 6.40, N 8.09; Found C 76.08, H 
6.21, N 7.88.
Diethyl 4,4'-(1-methylimidazole-2,5-diyl)dibenzoate (4) 
From ethyl 4-bromobenzoate (0.687 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 4 was 
obtained in 55% (0.208 g) yield.  
1
H NMR (400 MHz, 
DMSOd6) δ  8.10 (d, J = 8.4 Hz, 2H), 8.07 (d, J = 8.4 Hz, 
2H), 7.92 (d, J = 8.4 Hz, 2H), 7.73 (d, J = 8.4 Hz, 2H), 7.39 
(s, 1H), 4.36 (q, J = 7.5 Hz, 4H), 3.77 (s, 3H), 1.35 (t, J = 
7.5 Hz, 6H).  
13
C NMR (100 MHz, DMSOd6) δ 165.9, 
165.8, 149.0, 135.3, 135.2, 134.6, 130.1, 130.0, 129.8, 
129.5, 129.2, 129.1, 128.5, 61.4, 61.3, 34.8, 14.6.  
C22H22N2O4 (378.42): Calcd C 69.83, H 5.86, N 7.40; 
Found C 69.71, H 5.70, N 7.55.
4,4'-(1-Methylimidazole-2,5-diyl)dibenzaldehyde (5) 
From 4-bromobenzaldehyde (0.555 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 5 was 
obtained in 62% (0.180 g) yield.  
1
H NMR (400 MHz, 
CDCl3) δ  10.03 (s, 1H), 10.01 (s, 1H), 7.96 (d, J = 8.4 Hz, 
2H), 7.93 (d, J = 8.4 Hz, 2H), 7.85 (d, J = 8.4 Hz, 2H), 7.59 
(d, J = 8.4 Hz, 2H), 7.33 (s, 1H), 3.73 (s, 3H).  13C NMR 
(100 MHz, CDCl3) δ 191.6, 191.4, 149.3, 136.2, 135.9, 
135.6, 131.5, 130.3, 130.0, 129.8, 129.2, 128.7, 127.5, 34.4.  
C18H14N2O2 (290.32): Calcd C 74.47, H 4.86, N 9.65; 
Found C 74.55, H 4.99, N 9.47.
4,4'-(1-Methylimidazole-2,5-diyl)dibenzonitrile (6) 
From 4-bromobenzonitrile (0.546 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 6 was 
obtained in 60% (0.170 g) yield.  1H NMR (400 MHz, 
CDCl3) δ  7.83 (d, J = 8.4 Hz, 2H), 7.73 (d, J = 8.4 Hz, 
4H), 7.55 (d, J = 8.4 Hz, 2H), 7.28 (s, 1H), 3.70 (s, 3H).  
13C NMR (100 MHz, CDCl3) δ 148.6, 134.9, 134.1, 133.9, 
132.8, 132.6, 129.5, 129.3, 128.8, 118.4, 118.3, 112.9, 
112.0, 34.4.  C18H12N4 (284.31): Calcd C 76.04, H 4.25, N 
19.71; Found C 76.18, H 4.08, N 19.99.
1-Methyl-2,5-bis(4-nitrophenyl)-imidazole (7) 
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From 4-bromonitrobenzene (0.606 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 7 was 
obtained in 32% (0.104 g) yield.  
1
H NMR (400 MHz, 
DMSOd6) δ  8.39 (d, J = 8.4 Hz, 2H), 8.36 (d, J = 8.4 Hz, 
2H), 8.07 (d, J = 8.4 Hz, 2H), 7.89 (d, J = 8.4 Hz, 2H), 7.55 
(s, 1H), 3.83 (s, 3H).  
13
C NMR (100 MHz, DMSOd6) δ
148.7, 147.6, 147.0, 136.8, 136.4, 135.1, 130.9, 130.0, 
129.3, 124.6, 124.3, 35.0.  C16H12N4O4 (324.29): Calcd C 
59.26, H 3.73, N 17.28; Found C 59.04, H 3.49, N 17.38. 
2,5-Bis(4-fluorophenyl)-1-methylimidazole (8) 
From 4-bromofluorobenzene (0.525 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 8 was 
obtained in 78% (0.210 g) yield.  
1
H NMR (400 MHz, 
CDCl3) δ  7.65-7.55 (m, 2H), 7.40-7.30 (m, 2H), 7.15-7.00 
(m, 5H), 3.57 (s, 3H).  
13
C NMR (100 MHz, CDCl3) 
δ 163.1 (d, J = 249.0 Hz), 162.7 (d, J = 249.0 Hz), 148.4, 
134.4, 130.7 (d, J = 8.3 Hz), 130.5 (d, J = 8.3 Hz), 127.4, 
126.9 (d, J = 3.3 Hz), 126.2 (d, J = 3.3 Hz), 115.9 (d, J = 
17.3 Hz), 115.7 (d, J = 17.3 Hz), 33.6.  C16H12F2N2
(270.28): Calcd C 71.10, H 4.48, N 10.36; Found C 71.02, 
H 4.34, N 10.17.
1-Methyl-2,5-diphenylimidazole (9)
9b
  
From 4-bromobenzene (0.471 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 9 was 
obtained in 80% (0.187 g) yield.  
1
H NMR (400 MHz, 
CDCl3) δ  7.63 (d, J = 8.4 Hz, 2H), 7.45-7.25 (m, 8H), 7.14 
(s, 1H), 3.62 (s, 3H).
1-Methyl-2,5-dip-tolylimidazole (10) 
From 4-bromotoluene (0.513 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 10 
was obtained in 81% (0.212 g) yield.
1H NMR (400 MHz, CDCl3) δ  7.52 (d, J = 8.4 Hz, 2H), 
7.27 (d, J = 8.4 Hz, 4H), 7.23-7.17 (m, 4H), 7.10 (s, 1H), 
3.58 (s, 3H), 2.34 (s, 6H).  13C NMR (100 MHz, CDCl3) δ
148.9, 139.0, 138.0, 135.3, 129.5, 129.3, 128.8, 128.7, 
127.4, 127.1, 126.2, 33.8, 21.4, 21.3.  C18H18N2 (262.35): 
Calcd C 82.41, H 6.92, N 10.68; Found C 82.50, H 6.98, N 
10.89.
2,5-Bis(4-methoxyphenyl)-1-methylimidazole (11)
8c
  
From 4-bromoanisole (0.561 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 11 
was obtained in 78% (0.229 g) yield.  
1
H NMR (400 MHz, 
CDCl3) δ  7.55 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.4 Hz, 
2H), 7.04 (s, 1H), 6.93 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 8.4 
Hz, 2H), 3.80 (s, 3H), 3.79 (s, 3H), 3.55 (s, 3H).
1-Methyl-2,5-bis(3-nitrophenyl)-imidazole (12) 
From 3-bromonitrobenzene (0.606 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 12 
was obtained in 62% (0.201 g) yield.  
1
H NMR (400 MHz, 
CDCl3) δ  8.52 (s, 1H), 8.35-8.15 (m, 3H), 8.05 (d, J = 8.4 
Hz, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 8.4 Hz, 1H), 
7.62 (d, J = 8.4 Hz, 1H), 7.25 (s, 1H), 3.72 (s, 3H).  
13
C 
NMR (100 MHz, CDCl3) δ 148.6, 148.4, 147.9, 134.7, 
134.3, 134.0, 131.9, 131.3, 130.1, 130.0, 129.4, 123.8, 
123.4, 123.1, 123.0, 34.0.  C16H12N4O4 (324.29): Calcd C 
59.26, H 3.73, N 17.28; Found C 59.40, H 3.61, N 17.10.
3,3'-(1-Methylimidazole-2,5-diyl)dibenzonitrile (13) 
From 3-bromobenzonitrile (0.546 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 13 
was obtained in 60% (0.170 g) yield.  
1
H NMR (400 MHz, 
CDCl3) δ  7.99 (s, 1H), 7.98 (d, J = 8.4 Hz, 1H), 7.75-7.65 
(m, 4H), 7.61 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 
7.23 (s, 1H), 3.68 (s, 3H).  
13
C NMR (100 MHz, CDCl3) δ
146.8, 134.1, 133.4, 133.2, 133.1, 132.4, 132.3, 132.1, 
130.2, 130.1, 130.0, 118.0, 117.9, 113.6, 113.3, 34.2.  
C18H12N4 (284.31): Calcd C 76.04, H 4.25, N 19.71; Found 
C 76.29, H 4.22, N 19.50.
1-Methyl-2,5-bis(3-(trifluoromethyl)phenyl)-imidazole 
(14) 
From 3-bromobenzotrifluoride (0.675 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 14 
was obtained in 59% (0.218 g) yield.  
1
H NMR (400 MHz, 
CDCl3) δ  7.92 (s, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.65-7.50 
(m, 6H), 7.21 (s, 1H), 3.63 (s, 3H).  
13
C NMR (100 MHz, 
CDCl3) δ 148.5, 134.5, 131.9, 131.8, 131.5 (q, J = 20.4 
Hz), 131.4, 131.1 (q, J = 20.4 Hz), 130.7, 129.4, 129.2, 
128.6, 125.7, (q, J = 3.7 Hz), 125.6 (q, J = 3.7 Hz), 125.3 
(q, J = 3.7 Hz), 124.8 (q, J = 3.7 Hz), 122.5, 33.8.  
C18H12F6N2 (370.29): Calcd C 58.38, H 3.27, N 7.57; 
Found C 58.47, H 3.45, N 7.42.
1-Methyl-2,5-dim-tolylimidazole (15) 
From 3-bromotoluene (0.513 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 15 
was obtained in 79% (0.207 g) yield.  
1
H NMR (400 MHz, 
CDCl3) δ  7.50 (s, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.30 (d, J 
= 8.4 Hz, 1H), 7.26 (d, J = 8.4 Hz, 1H), 7.22-7.10 (m, 5H), 
3.59 (s, 3H), 2.35 (s, 3H), 2.34 (s, 3H).  13C NMR (100 
MHz, CDCl3) δ 174.1, 149.1, 138.5, 138.4, 135.5, 130.3, 
130.0, 129.7, 129.5, 128.8, 128.7, 128.4, 126.7, 125.8, 
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125.7, 33.8, 21.5, 21.4.  C18H18N2 (262.35): Calcd C 82.41, 
H 6.92, N 10.68; Found C 82.27, H 6.90, N 10.51.
2,5-bis(3,5-bis(trifluoromethyl)phenyl)-1-
methylimidazole (16a) 
From 3,5-bis(trifluoromethyl)bromobenzene (0.879 g, 3 
mmol), 1-methylimidazole (0.082 g, 1 mmol) and CsOAc 
(1.303 g, 4 mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), 
product 16a was obtained in 48% (0.243 g) yield.  The 
2,4,5-triarylated imidazole 16b was also isolated in 30% 
(0.215 g) yield.  16a:  
1
H NMR (400 MHz, CDCl3) δ  8.13 
(s, 2H), 7.89 (s, 1H), 7.85 (s, 3H), 7.31 (s, 1H), 3.70 (s, 
3H).  13C NMR (100 MHz, CDCl3) δ 147.6, 133.8, 132.7 
(q, J = 26.2 Hz), 132.1 (q, J = 26.2 Hz), 131.5, 129.6, 
128.5, 128.4, 124.3, 122.8 (quint., J = 3.6 Hz), 122.1 
(quint., J = 3.6 Hz), 121.6, 118.9, 33.9.  C20H10F12N2
(506.29): Calcd C 47.45, H 1.99, N 5.53; Found C 47.40, H 
2.09, N 5.36.  16b:  
1
H NMR (400 MHz, CDCl3) δ  8.18 (s, 
2H), 8.00 (s, 1H), 7.96 (s, 1H), 7.84 (s, 4H), 7.66 (s, 1H), 
3.59 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 145.7, 136.4, 
134.0, 132.3 (q, J = 34.8 Hz), 131.5 (q, J = 34.8 Hz), 130.9 
(q, J = 34.8 Hz), 130.7, 130.6, 129.6 (m), 128.6, 128.0 (m), 
122.4 (m), 122.2 (m), 120.0 (m), 121.7 (q, J = 270.0 Hz), 
121.6 (q, J = 270.0 Hz), 121.5 (q, J = 270.0 Hz), 32.6.  
C28H12F18N2 (718.38): Calcd C 46.81, H 1.68, N 3.90; 
Found C 46.99, H 1.88, N 3.99.
2,2'-(1-Methylimidazole-2,5-diyl)dibenzonitrile (17) 
From 2-bromobenzonitrile (0.546 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 17 
was obtained in 78% (0.221 g) yield.  
1
H NMR (400 MHz, 
CDCl3) δ  7.76 (d, J = 8.4 Hz, 2H), 7.70-7.65 (m, 3H), 
7.58-7.45 (m, 3H), 7.38 (s, 1H), 3.53 (s, 3H).  
13
C NMR 
(100 MHz, CDCl3) δ 146.7, 134.1, 133.7, 133.6, 133.2, 
133.0, 132.9, 131.7, 131.6, 131.3, 130.5, 129.7, 129.0, 
117.9, 117.8, 113.1, 33.3.  C18H12N4 (284.31): Calcd C 
76.04, H 4.25, N 19.71; Found C 76.09, H 4.31, N 19.57.
2,5-Bis(2-fluorophenyl)-1-methylimidazole (18) 
From 2-bromofluorobenzene (0.525 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 18 
was obtained in 59% (0.159 g) yield.  
1
H NMR (400 MHz, 
CDCl3) δ  7.56 (t, J = 8.0 Hz, 1H), 7.42-7.30 (m, 3H), 7.25-
7.08 (m, 5H), 3.42 (s, 3H).  
13
C NMR (100 MHz, CDCl3) δ
160.0 (dd, J = 249.2, 7.4 Hz), 144.7, 132.4 (d, J = 2.7 Hz), 
131.9 (d, J = 2.7 Hz), 131.2 (d, J = 8.1 Hz), 130.4 (d, J = 
8.1 Hz), 129.3, 124.6 (d, J = 3.4 Hz), 124.4 (d, J = 3.4 Hz), 
119.1 (d, J = 14.9 Hz), 118.1 (d, J = 14.9 Hz), 116.1 (d, J = 
13.2 Hz), 115.9 (d, J = 13.2 Hz), 32.4.  C16H12F2N2
(270.28): Calcd C 71.10, H 4.48, N 10.36; Found C 71.27, 
H 4.55, N 10.51.
1-Methyl-2,5-dio-tolylimidazole (19) 
From 2-bromotoluene (0.513 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 19 
was obtained in 54% (0.141 g) yield.  
1
H NMR (400 MHz, 
CDCl3) δ  7.38-7.15 (m, 8H), 7.03 (s, 1H), 3.11 (s, 3H), 
2.21 (s, 3H), 2.18 (s, 3H).  
13
C NMR (100 MHz, CDCl3) δ
147.7, 138.2, 132.4, 131.3, 130.6, 130.5, 130.4, 130.3, 
129.7, 129.4, 129.0, 126.7, 125.9, 125.8, 31.5, 20.0, 19.7.  
C18H18N2 (262.35): Calcd C 82.41, H 6.92, N 10.68; Found 
C 82.50, H 6.98, N 10.40.
3,3'-(1-Methylimidazole-2,5-diyl)dipyridine (20) 
From 3-bromopyridine (0.474 g, 3 mmol), 1-
methylimidazole (0.082 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 20 
was obtained in 72% (0.170 g) yield.  
1
H NMR (400 MHz, 
CDCl3) δ  8.89 (s, 1H), 8.68 (s, 1H), 8.62 (d, J = 4.6 Hz, 
1H), 8.58 (d, J = 4.6 Hz, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.73 
(d, J = 8.0 Hz, 1H), 7.40-7.34 (m, 2H), 7.34 (s, 1H), 3.66 
(s, 3H).  13C NMR (100 MHz, CDCl3) δ 149.9, 149.4, 
149.3, 149.2, 147.1, 136.3, 135.9, 132.6, 128.9, 126.6, 
125.9, 123.7, 123.6, 33.7.  C14H12N4 (236.27): Calcd C 
71.17, H 5.12, N 23.71; Found C 71.08, H 5.20, N 23.49.
1-n-Butyl-2,5-bis(4-chlorophenyl)-imidazole (21b) 
From 4-bromochlorobenzene (0.574 g, 3 mmol), 1-
butylimidazole (0.124 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 21b 
was obtained in 24% (0.083 g) yield.  1H NMR (400 MHz, 
CDCl3) δ  7.48 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 8.4 Hz, 
2H), 7.38 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.4 Hz, 2H), 7.06 
(s, 1H), 3.99 (t, J = 7.5 Hz, 2H), 1.26-1.15 (m, 2H), 0.90-
0.83 (m, 2H), 0.57 (t, J = 7.5 Hz, 3H).  
13
C NMR (100 
MHz, CDCl3) δ 148.3, 135.0, 134.2, 133.6, 130.2, 130.1, 
129.9, 129.1, 128.9, 128.5, 44.9, 32.4, 19.3, 13.3.  
C19H18Cl2N2 (345.27): Calcd C 66.09, H 5.25, N 8.11; 
Found C 66.14, H 5.08, N 7.89.  The mono-arylation 
product 21a was also isolated in 45% yield (0.105 g): 
1
H 
NMR (400 MHz, CDCl3) δ  7.50 (s, 1H), 7.34 (d, J = 8.4 
Hz, 2H), 7.23 (d, J = 8.4 Hz, 2H), 6.98 (s, 1H), 3.87 (t, J = 
7.5 Hz, 2H), 1.53 (quint., J = 7.5 Hz, 2H), 1.16 (sext., J = 
7.5 Hz, 2H), 0.77 (t, J = 7.5 Hz, 3H).  13C NMR (100 MHz, 
CDCl3) δ 138.3, 134.0, 131.7, 130.0, 129.0, 128.7, 128.3, 
45.1, 32.9, 19.6, 13.4. 
2,5-Bis(3,5-bis(trifluoromethyl)phenyl)-1-
butylimidazole (22b) 
From 3,5-bis(trifluoromethyl)bromobenzene (0.879 g, 3 
mmol), 1-butylimidazole (0.124 g, 1 mmol) and CsOAc 
(1.303 g, 4 mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), 
product 22b was obtained in 35% (0.192 g) yield.  
1
H NMR 
(400 MHz, CDCl3) δ  8.05 (s, 2H), 7.91 (s, 1H), 7.88 (s, 
1H), 7.84 (s, 2H), 7.26 (s, 1H), 4.04 (t, J = 7.5 Hz, 2H), 
1.40-1.25 (m, 2H), 1.05-0.90 (m, 2H), 0.60 (t, J = 7.5 Hz, 
3H).  13C NMR (100 MHz, CDCl3) δ 147.3, 133.0-131.5 
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(m), 130.4, 128.8, 128.6, 127.1, 124.4, 122.8 (q, J = J = 3.7 
Hz), 122.1 (q, J = 3.7 Hz), 121.6, 118.9, 45.4, 32.6, 19.2, 
13.0.  C23H16F12N2 (548.37): Calcd C 50.38, H 2.94, N 
5.11; Found C 50.19, H 2.78, N 4.83.  The 2,4,5-tri-
arylation product 22c was also isolated in 33% yield (0.251 
g): 
1
H NMR (400 MHz, CDCl3) δ  8.11 (s, 2H), 8.02 (s, 
1H), 7.97 (s, 1H), 7.85 (s, 2H), 7.78 (s, 2H), 7.64 (s, 1H), 
3.89 (t, J = 7.5 Hz, 2H), 1.40-1.25 (m, 2H), 1.05-0.90 (m, 
2H), 0.60 (t, J = 7.5 Hz, 3H). 
1-n-Butyl-2,5-dip-tolylimidazole (23b) 
From 4-bromotoluene (0.513 g, 3 mmol), 1-butylimidazole 
(0.124 g, 1 mmol) and CsOAc (1.303 g, 4 mmol) with 
Pd(OAc)2 (4.4 mg, 0.02 mmol), product 23b was obtained 
in 25% (0.076 g) yield.  
1
H NMR (400 MHz, CDCl3) δ 
7.46 (d, J = 8.4 Hz, 2H), 7.25 (d, J = 8.4 Hz, 2H), 7.23-7.17 
(m, 4H), 7.02 (s, 1H), 3.99 (t, J = 7.5 Hz, 2H), 2.34 (s, 6H), 
1.26-1.15 (m, 2H), 0.90-0.83 (m, 2H), 0.54 (t, J = 7.5 Hz, 
3H).  13C NMR (100 MHz, CDCl3) δ 149.1, 138.5, 137.8, 
134.3, 129.4, 129.2, 128.8, 128.7, 128.0, 127.7, 44.7, 32.3, 
21.4, 21.3, 19.3, 13.3.  C21H24N2 (304.43): Calcd C 82.85, 
H 7.95, N 9.20; Found C 82.67, H 8.14, N 9.02.  The 
mono-arylation product 23a was also isolated in 31% yield 
(0.066 g): 1H NMR (400 MHz, CDCl3) δ  7.46 (s, 1H), 
7.20-7.16 (m, 4H), 6.95 (s, 1H), 3.87 (t, J = 7.5 Hz, 2H), 
2.34 (s, 3H), 1.60-1.40 (m, 2H), 1.20-1.05 (m, 2H), 0.77 (t, 
J = 7.5 Hz, 3H).  
13
C NMR (100 MHz, CDCl3) δ 137.8, 
132.9, 129.4, 128.7, 127.9, 127.3, 45.0, 32.9, 21.2, 19.7, 
13.5. 
5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-imidazole 
(24a) 
From 4-bromochlorobenzene (0.574 g, 3 mmol), 1-(4-
methoxyphenyl)-imidazole (0.174 g, 1 mmol) and CsOAc 
(1.303 g, 4 mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), 
product 25a was obtained in 62% (0.176 g) yield.  
1
H NMR 
(400 MHz, CDCl3) δ  7.57 (s, 1H), 7.16 (d, J = 8.4 Hz, 2H), 
7.13 (s, 1H), 7.02 (d, J = 8.4 Hz, 2H), 6.99 (d, J = 8.4 Hz, 
2H), 6.83 (d, J = 8.4 Hz, 2H), 3.76 (s, 3H).  
13
C NMR (100 
MHz, CDCl3) δ 159.4, 139.4, 133.4, 132.1, 129.3, 129.2, 
128.8, 128.7, 128.0, 127.0, 114.7, 55.5.  C16H13ClN2O 
(284.74): Calcd C 67.49, H 4.60, N 9.84; Found C 67.28, H 
4.37, N 10.08. 
5-(3,5-Bis(trifluoromethyl)phenyl)-1-(4-
methoxyphenyl)-imidazole (25a) 
From 3,5-bis(trifluoromethyl)bromobenzene (0.879 g, 3 
mmol), 1-(4-methoxyphenyl)-imidazole (0.174 g, 1 mmol) 
and CsOAc (1.303 g, 4 mmol) with Pd(OAc)2 (4.4 mg, 0.02 
mmol), product 25a was obtained in 75% (0.289 g) yield.  
1
H NMR (400 MHz, CDCl3) δ  7.62 (s, 1H), 7.62 (s, 1H), 
7.46 (s, 2H), 7.35 (s, 1H), 7.05 (d, J = 8.4 Hz, 2H), 6.88 (d, 
J = 8.4 Hz, 2H), 3.76 (s, 3H).  
13
C NMR (100 MHz, CDCl3) 
δ 160.0, 140.4, 131.7 (q, J = 34.0 Hz), 130.4, 130.1, 128.4, 
127.3 (m), 127.1, 123.0 (q, J = 272.7 Hz), 120.6 (m), 115.0, 
55.6.  C18H12F6N2O (386.29): Calcd C 55.97, H 3.13, N 
7.25; Found C 55.79, H 3.20, N 7.41.  The di-arylation 
product 25b was also isolated in low yield: 
1
H NMR (400 
MHz, CDCl3) δ  7.79 (s, 2H), 7.70 (s, 1H), 7.66 (s, 1H), 
7.50 (s, 1H), 7.47 (s, 2H), 7.03 (d, J = 8.4 Hz, 2H), 6.92 (d, 
J = 8.4 Hz, 2H), 3.78 (s, 3H). 
4-(5-(4-Chlorophenyl)-imidazol-1-yl)benzaldehyde (26a) 
From 4-bromochlorobenzene (0.574 g, 3 mmol), 4-(1-
imidazol-1-yl)benzaldehyde (0.172 g, 1 mmol) and CsOAc 
(1.303 g, 4 mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), 
product 26a was obtained in 53% (0.149 g) yield.  1H NMR 
(400 MHz, CDCl3) δ  9.97 (s, 1H), 7.87 (d, J = 8.4 Hz, 2H), 
7.70 (s, 1H), 7.27 (d, J = 8.4 Hz, 2H), 7.22 (s, 1H), 7.20 (d, 
J = 8.4 Hz, 2H), 6.99 (d, J = 8.4 Hz, 2H).  
13
C NMR (100 
MHz, CDCl3) δ 190.7, 141.1, 135.6, 134.0, 131.0, 130.0, 
129.4, 129.0, 127.4, 125.7.  C16H11ClN2O (282.72): Calcd 
C 67.97, H 3.92, N 9.91; Found C 67.75, H 3.97, N 9.72. 
4-(5-(3,5-Bis(trifluoromethyl)phenyl)-imidazol-1-
yl)benzaldehyde (27a) 
From 3,5-bis(trifluoromethyl)bromobenzene (0.879 g, 3 
mmol), 4-(1-imidazol-1-yl)benzaldehyde (0.172 g, 1 mmol) 
and CsOAc (1.303 g, 4 mmol) with Pd(OAc)2 (4.4 mg, 0.02 
mmol), product 27a was obtained in 52% (0.200 g) yield.  
Trace of diarylation product were observed by GC/MS 
analysis of the crude mixture.  
1
H NMR (400 MHz, CDCl3) 
δ  10.00 (s, 1H), 7.92 (d, J = 8.4 Hz, 2H), 7.77 (s, 1H), 7.70 
(s, 1H), 7.47 (s, 2H), 7.40 (s, 1H), 7.30 (d, J = 8.4 Hz, 2H).  
13
C NMR (100 MHz, CDCl3) δ 190.4, 140.4, 139.9, 136.1, 
132.2 (q, J = 34.0 Hz), 131.4, 131.2, 131.1, 127.7 (m), 
126.0, 122.4 (q, J = 272.7 Hz), 121.3 (m).  C18H10F6N2O 
(384.28): Calcd C 56.26, H 2.62, N 7.29; Found C 56.41, H 
2.47, N 7.48. 
4-(1-Benzylimidazol-5-yl)benzonitrile (28a) 
From 4-bromobenzonitrile (0.546 g, 3 mmol), 1-
benzylimidazole (0.158 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 28a 
was obtained in 41% (0.106 g) yield.  1H NMR (400 MHz, 
CDCl3) δ  7.57 (s, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.31 (d, J 
= 8.4 Hz, 2H), 7.26-7.20 (m, 3H), 7.17 (s, 1H), 6.93 (d, J = 
8.4 Hz, 2H), 5.13 (s, 2H).  13C NMR (100 MHz, CDCl3) δ
140.2, 136.1, 134.3, 132.5, 131.7, 130.0, 129.1, 128.8, 
128.3, 126.4, 118.5, 111.5, 49.1.  C17H13N3 (259.31): Calcd 
C 78.74, H 5.05, N 16.20; Found C 78.40, H 4.99, N 15.91. 
1-Benzyl-2,5-bis(3,5-bis(trifluoromethyl)phenyl)-
imidazole (29b) 
From 3,5-bis(trifluoromethyl)bromobenzene (0.879 g, 3 
mmol), 1-benzylimidazole (0.158 g, 1 mmol) and CsOAc 
(1.303 g, 4 mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), 
product 29b was obtained in 32% (0.186 g) yield.  
1
H NMR 
(400 MHz, CDCl3) δ  8.01 (s, 2H), 7.81 (s, 1H), 7.76 (s, 
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1H), 7.67 (s, 2H), 7.38 (s, 1H), 7.28-7.20 (m, 3H), 6.81 (d, 
J = 8.4 Hz, 2H), 5.19 (s, 2H).  
13
C NMR (100 MHz, CDCl3) 
δ 147.7, 135.8, 133.5, 132.4 (q, J = 34.0 Hz), 132.3 (q, J = 
34.0 Hz), 132.2, 131.6, 130.4, 129.4, 128.7 (m), 128.5, 
125.4, 122.9 (q, J = 272.7 Hz), 122.8 (m), 122.7 (q, J = 
272.7 Hz), 122.0 (m), 49.3.  C26H14F12N2 (582.38): Calcd C 
53.62, H 2.42, N 4.81; Found C 53.60, H 2.54, N 4.88.  The 
2,4,5-tri-arylation product 30c was also isolated in 34% 
yield (0.269 g): 1H NMR (400 MHz, CDCl3) δ  8.00 (s, 
2H), 7.89 (s, 1H), 7.87 (s, 1H), 7.84 (s, 2H), 7.64 (s, 1H), 
7.59 (s, 2H), 7.25-7.20 (m, 3H), 6.73 6.81 (d, J = 8.4 Hz, 
2H), 5.08 (s, 2H).  
13
C NMR (100 MHz, CDCl3) δ 146.9, 
137.7, 135.2, 134.9, 133.1 (q, J = 34.0 Hz), 132.5 (q, J = 
34.0 Hz), 131.1, 131.7, 131.6, 130.8 (m), 129.4, 129.0 (m), 
128.7, 126.5 (m), 125.6, 123.3 (m), 122.9 (q, J = 272.7 Hz), 
122.7 (q, J = 272.7 Hz), 122.5 (q, J = 272.7 Hz), 120.9 (m), 
49.4
1-Benzyl-5-(4-chlorophenyl)-imidazole (30a)
10a
From 4-bromochlorobenzene (0.574 g, 3 mmol), 1-
benzylimidazole (0.158 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 30a 
was obtained in 44% (0.118 g) yield.  1H NMR (400 MHz, 
CDCl3) δ  7.51 (s, 1H), 7.28-7.15 (m, 5H), 7.12 (d, J = 8.4 
Hz, 2H), 7.06 (s, 1H), 6.92 (d, J = 8.4 Hz, 2H), 5.06 (s, 
2H).  13C NMR (100 MHz, CDCl3) δ 139.0, 136.5, 134.2, 
132.3, 130.1, 129.0, 128.9, 128.6, 128.2, 128.1, 126.5, 48.8.  
The di-arylation product 30b was also isolated: 
1
H NMR 
(400 MHz, CDCl3) δ  7.43 (d, J = 8.4 Hz, 2H), 7.27 (d, J = 
8.4 Hz, 2H), 7.21-7.16 (m, 6H), 7.13 (d, J = 8.4 Hz, 2H), 
6.77 (d, J = 8.4 Hz, 2H), 5.15 (s, 2H).
1-Benzyl-5-p-tolylimidazole (31a)
10a
From 4-bromotoluene (0.513 g, 3 mmol), 1-
benzylimidazole (0.158 g, 1 mmol) and CsOAc (1.303 g, 4 
mmol) with Pd(OAc)2 (4.4 mg, 0.02 mmol), product 31a 
was obtained in 31% (0.077 g) yield.  
1
H NMR (400 MHz, 
CDCl3) δ  7.48 (s, 1H), 7.30-7.15 (m, 3H), 7.10 (s, 4H), 
7.04 (s, 1H), 6.95 (d, J = 8.0 Hz, 2H), 5.06 (s, 2H), 2.29 (s, 
3H).  
13
C NMR (100 MHz, CDCl3) δ 138.4, 138.0, 136.9, 
133.5, 129.4, 128.9, 128.8, 128.0, 127.9, 126.8, 126.7, 48.7, 
21.2.  The di-arylation product 31b was also isolated: 
1
H 
NMR (400 MHz, CDCl3) δ  7.37 (d, J = 8.4 Hz, 2H), 7.20-
7.00 (m, 10H), 6.77 (d, J = 8.4 Hz, 2H), 5.17 (s, 2H), 2.26 
(s, 3H), 2.25 (s, 3H).  
13
C NMR (100 MHz, CDCl3) δ
138.7, 138.0, 137.9, 134.9, 129.3, 129.2, 128.9, 128.7, 
128.6, 128.2, 127.9, 127.3, 125.8, 48.4, 21.3, 21.2.
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